Study on Correlation Between Vascular ET-1 and Adiponectin in Pediatric Obesity
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Monica Montagnani, Montagnani, Monica, M.D., Ph.D.
First received: December 12, 2012
Last updated: NA
Last verified: December 2012
History: No changes posted
The aim of this study is to explore whether and how high circulating levels of endothelin-1 (ET-1) in obese and overweight children may contribute to impair adiponectin (Ad) production, release and vascular activity
||Observational Model: Cohort
Time Perspective: Retrospective
||Observational Retrospective Study on Correlation Between ET-1 and Ad in Obese Children
Biospecimen Retention: Samples Without DNA
Primary Outcome Measures:
- Correlation between serum levels of ET-1 and Ad in lean, overweight and obese children [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||March 2013 (Final data collection date for primary outcome measure)
Overweight Children (OW)
Obese children (Ob)
|Ages Eligible for Study:
||5 Years to 13 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
CHILDREN ATTENDING THE OUTPATIENT UNIT OF THE UNIVERSITY PEDIATRIC CLINIC
- Children will be enrolled into lean, overweight or obese groups based on Body mass index (BMI) calculated according to standard methods. International standards for sex-and age-specific BMI centiles for subjects aged 2-18 years will be used. The 95th centile of BMI reference is the cut off point for childhood obesity. Overweight and obese children are defined as those with a BMI higher than the centile curves.
- presence of renal, liver and/or cardiovascular diseases;
- metabolic and/or endocrine disorders;
- genetic syndromes;
- histories of chronic allergies, acute infectious or inflammatory diseases during the last 3 months preceding the study
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01750333
|University of Bari Medical School - Dept Biomedical Sciences and Human Oncology
|Bari, Italy, 70124 |
||Monica Montagnani, MD, PhD
||University of Bari Medical School
No publications provided
||Monica Montagnani, Medical School Faculty Member - Professor of Pharmacology, Montagnani, Monica, M.D., Ph.D.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 12, 2012
||December 12, 2012
||Italy: Ministry of Health
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 18, 2014
Signs and Symptoms
Glucose Metabolism Disorders